Document text
Principal Investigator: SUMIT K CHANDA
Organization: SCRIPPS RESEARCH INSTITUTE, THE
Fiscal Year: 2022
Award: $2,050,508
Funding agency: National Institute of Allergy and Infectious Diseases
SUMMARY
The Administrative Core will coordinate the CAMPP AViDD Center by 1) establishing an organizational
structure centered on an Executive Committee responsible for – along with Director, Deputy Directors,
and Scientific Advisory Board (SAB) – monitoring overall program progress and making decisions on
staffing plans, allocation of resources, core usage, and other policies; 2) coordinating regularly held
conference calls between the Center’s research teams and organizing annual meetings between the
PIs, selected key personnel, the SAB and NIAID, as well as annual reverse site visits at NIAID; 3)
assisting the investigators of this consortium in reagent and data sharing, manuscript preparations, IND
preparations, the timely public dissemination of data, and the submission of annual progress reports to
NIAID; and 4) providing support to early career research scientists and established investigators in
other fields to develop independent research skills in antiviral drug research and development by
implementing Developmental Research Projects and Mentored Project Programs. The Core Director
has significant expertise in the coordination of program projects and large-scale multi-institutional
consortia. He served as Director of the HINT consortium, a program project consisting of over 13 PIs
at 10 institutions focusing on systems-based analysis of immune responses to HIV (P01 AI090935),
and as Deputy Director of additional multi-institutional consortia; Fluomics (U19 AI106754) and
Fluomics: The Next Generation (U19 AI135972), which focus on the use of systems-level technologies
to identify host determinants of viral pathogenesis, both for influenza and SARS-CoV-2. More recently,
he was named the PD/PI on a multi-PD/PI NIAID Vaccine Adjuvant Discovery Program contract
(75N93019C00046), the PD/PI on the multi-PD/PI NIAID Reversing Immune Dysfunction for HIV-1
Eradication Program (UM1 AI164561), and the PD of the DoD program Development and Advancement
of Broad-Spectrum Respiratory Antivirals (DABRA) (W81XWH-20-1-0270). Core Deputy Director Dr.
García-Sastre has been the PD of the two Fluomics programs as well as the DABRA program
mentioned above and is thus very well suited to assist Dr. Chanda in successfully leading this multi-
disciplinary program. Deputy Director García-Sastre will oversee the Mentored Project to be initiated in
year 2, supported by his experience in organizing the highly successful Fluomics program for junior
level investigators (EMBED). Deputy Director Dr. Arnab Chatterjee will take responsibility for oversight
of the Developmental Research program and has substantial experience relevant to the development
and advancement of specific antivirals and related basic science studies, having advanced multiple
drug candidates to major technology development licensing deals with Bristol-Myers Squibb, AbbVie,
and Gilead as well as clinical trials.
Terms: <2019 novel corona virus><2019 novel coronavirus><2019-nCoV><AIDS Virus><Acquired Immune Deficiency Syndrome Virus><Acquired Immunodeficiency Syndrome Virus><Antiviral Agents><Antiviral Drugs><Antivirals><Basic Research><Basic Science><COVID-19 virus><COVID19 virus><Clinical Trials><CoV-2><CoV2><Collaborations><Communication><Contracting Opportunities><Contracts><Coronaviridae><Coronavirus><Cyclicity><Decision Making><Development><Development and Research><Disputes><Foundations><Goals><Grant><Grippe><HIV><HIV-1><HIV-I><HIV1><Human Immunodeficiency Virus Type 1><Human Immunodeficiency Viruses><Human Resources><Human immunodeficiency virus 1><Immune Diseases><Immune Disorders><Immune Dysfunction><Immune System Diseases><Immune System Disorder><Immune System Dysfunction><Immune System and Related Disorders><Immune response><Immunodeficiency and Immunosuppression Disorders><Immunologic Diseases><Immunological Diseases><Immunological Dysfunction><Immunological System Dysfunction><Immunological response><Influenza><Infrastructure><Institution><Investigators><LAV-HTLV-III><Laboratories><Licensing><Lymphadenopathy-Associated Virus><Manpower><Manuscripts><Medicine><Mentors><Mission><Modeling><Monitor><NIAID><Names><National Institute of Allergy and Infectious Disease><Organization Charts><Outcome><Performance><Periodicity><Personnel Management><Pharmaceutical Agent><Pharmaceuticals><Pharmacologic Substance><Pharmacological Substance><Policies><Preparation><Program Development><Progress Reports><Publications><R & D><R&D><R-Series Research Projects><R01 Mechanism><R01 Program><RNA Viruses><Reagent><Research><Research Grants><Research Personnel><Research Project Grants><Research Projects><Research Resources><Researchers><Resolution><Resource Allocation><Resource Sharing><Resources><Rhythmicity><SARS corona virus 2><SARS-CO-V2><SARS-COVID-2><SARS-CoV-2><SARS-CoV2><SARS-associated corona virus 2><SARS-associated coronavirus 2><SARS-coronavirus-2><SARS-related corona virus 2><SARS-related coronavirus 2><SARSCoV2><Sampling><Scientific Publication><Scientist><Services><Severe Acute Respiratory Coronavirus 2><Severe Acute Respiratory Distress Syndrome CoV 2><Severe Acute Respiratory Distress Syndrome Corona Virus 2><Severe Acute Respiratory Distress Syndrome Coronavirus 2><Severe Acute Respiratory Syndrome CoV 2><Severe Acute Respiratory Syndrome-associated coronavirus 2><Severe Acute Respiratory Syndrome-related coronavirus 2><Severe acute respiratory syndrome associated corona virus 2><Severe acute respiratory syndrome corona virus 2><Severe acute respiratory syndrome coronavirus 2><Severe acute respiratory syndrome related corona virus 2><Site Visit><System><Talents><Technology><Time><Travel><Vaccine Adjuvant><Viral Pathogenesis><Virus><Virus-HIV><Work><Wuhan coronavirus><anti-viral agents><anti-viral compound><anti-viral drugs><anti-viral medication><anti-viral therapeutic><anti-virals><antiviral compound><antiviral medication><antiviral therapeutic><base><career><career development><conference><convention><corona virus><coronavirus disease 2019 virus><coronavirus disease-19 virus><data deposition><data dissemination><data management><data sharing><data submission><developmental><drug candidate><drug discovery><experience><experiment><experimental research><experimental study><hCoV19><host response><immune system response><immunoresponse><industrial partnership><industry partner><industry partnership><meetings><member><multidisciplinary><nCoV2><next generation><organizational structure><pandemic><pandemic disease><pandemic preparedness><personnel><programs><research and development><respiratory><skills><summit><symposia><symposium><synergism><tech development><technology development><virus pathogenesis>